Literature DB >> 20456511

Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings.

I M Poynten1, F Jin, G P Prestage, J M Kaldor, S Kippax, A E Grulich.   

Abstract

OBJECTIVES: The aim of the study was to assess whether subpopulations with sufficiently high HIV incidences for HIV prevention trials can be identified in low HIV incidence settings such as Australia.
METHODS: In a community-based cohort study of HIV-negative homosexually active men in Sydney, Australia, potential risk factors associated with an annual HIV incidence of ≥2 per 100 person-years (PY) were identified. A stepwise procedure ranked these factors according to HIV incidence, to create a 'high-incidence' subgroup of participants. Willingness to participate in HIV prevention trials was assessed.
RESULTS: Although the incidence in the cohort overall was only 0.78 per 100 PY, nine risk variables were associated with an HIV incidence of 2 per 100 PY or greater. Stepwise inclusion of these variables revealed a 'high-incidence' subgroup of men representing 24% of the total follow-up time with a combined HIV incidence of 2.71 per 100 PY, who reported at least one of three risk factors in the past 6 months. These men were more willing than others to participate in vaccine and antiretroviral therapy HIV prevention trials.
CONCLUSIONS: These findings demonstrate that it is possible to identify high HIV incidence subpopulations in low-incidence settings such as Australia, and these men are of above average willingness to participate in HIV prevention trials.
© 2010 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456511     DOI: 10.1111/j.1468-1293.2010.00833.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  10 in total

1.  Rapid HIV Testing Is Highly Acceptable and Preferred among High-Risk Gay And Bisexual Men after Implementation in Sydney Sexual Health Clinics.

Authors:  Damian P Conway; Rebecca Guy; Stephen C Davies; Deborah L Couldwell; Anna McNulty; Don E Smith; Phillip Keen; Philip Cunningham; Martin Holt
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

2.  Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population.

Authors:  Damian P Conway; Martin Holt; Anna McNulty; Deborah L Couldwell; Don E Smith; Stephen C Davies; Philip Cunningham; Phillip Keen; Rebecca Guy
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 3.  Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis.

Authors:  Nga Thi Thu Vu; Lisa Maher; Iryna Zablotska
Journal:  J Int AIDS Soc       Date:  2015-01-16       Impact factor: 5.396

4.  COBA-Cohort: a prospective cohort of HIV-negative men who have sex with men, attending community-based HIV testing services in five European countries (a study protocol).

Authors:  Nicolas Lorente; Laura Fernàndez-López; Ricardo Fuertes; Daniela Rojas Castro; François Pichon; Bojan Cigan; Sophocles Chanos; Paula Meireles; Raquel Lucas; Stéphane Morel; Per Slaaen Kaye; Cristina Agustí; Irena Klavs; Tom Platteau; Jordi Casabona
Journal:  BMJ Open       Date:  2016-07-13       Impact factor: 2.692

5.  Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.

Authors:  S Vaccher; A Grulich; J McAllister; D J Templeton; M Bloch; A McNulty; J Holden; I M Poynten; G Prestage; I Zablotska
Journal:  BMJ Open       Date:  2016-06-20       Impact factor: 2.692

6.  Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project.

Authors:  Stefanie J Vaccher; Andrew E Grulich; Bridget G Haire; Damian P Conway; Isobel M Poynten; Catriona Ooi; Rosalind Foster; David J Templeton; Iryna B Zablotska
Journal:  PLoS One       Date:  2017-09-26       Impact factor: 3.240

7.  Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.

Authors:  Ellen White; David T Dunn; Monica Desai; Mitzy Gafos; Peter Kirwan; Ann K Sullivan; Amanda Clarke; Sheena McCormack
Journal:  Sex Transm Infect       Date:  2019-03-27       Impact factor: 3.519

8.  Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study.

Authors:  Kathleen E Ryan; Anne Mak; Mark Stoove; Brian Price; Christopher K Fairley; Simon Ruth; Luxshimi Lal; Jason Asselin; Carol El-Hayek; Long Nguyen; Colin Batrouney; David Wilson; John Lockwood; Dean Murphy; Vincent J Cornelisse; Norman Roth; Jeff Willcox; Christina C Chang; Judy Armishaw; Ban K Tee; Matthew Penn; George Forgan-Smith; Christopher Williams; Jeff Montgomery; Kat Byron; Alison Coelho; Brent Allen; Jeremy Wiggins; Jenny Kelsall; Olga Vujovic; Michael West; Anna B Pierce; Daniel Gallant; Charlotte Bell; John B F de Wit; Jennifer F Hoy; Steve L Wesselingh; Robert M Grant; Edwina J Wright
Journal:  Front Public Health       Date:  2018-05-29

9.  Different guidelines for pre-exposure prophylaxis (PrEP) eligibility estimate HIV risk differently: an incidence study in a cohort of HIV-negative men who have sex with men, Portugal, 2014-2018.

Authors:  Paula Meireles; Michael Plankey; Miguel Rocha; João Brito; Luís Mendão; Henrique Barros
Journal:  Euro Surveill       Date:  2020-07

10.  Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial.

Authors:  Vincent J Cornelisse; Christopher K Fairley; Mark Stoove; Jason Asselin; Eric P F Chow; Brian Price; Norman J Roth; Jeff Willcox; B K Tee; Matthew Penn; Christina C Chang; Judith Armishaw; George Forgan-Smith; Edwina J Wright
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.